VISION H2020 Project

Part of EU Open Research Repository
Published May 26, 2023 | Version v1
Journal article Open

Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue

Creators

  • 1. Molecular Epidemiology and Predictive Tumor Markers Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS); The Biomedical Research Network in Cancer (CIBERONC); Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS); Faculty of Medicine, University of Alcalá de Henares
  • 2. Institute of Tissue Medicine and Pathology, University of Bern
  • 3. Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences
  • 4. Molecular Epidemiology and Predictive Tumor Markers Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS); Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS)
  • 5. Experimental Oncology, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas (CNIO)
  • 6. Department of Molecular Oncology, Cancer Research Institute, Biomedical Research Center of the Slovak Academy of Sciences; Department of Surgical Oncology, National Cancer Institute, Slovak Medical University
  • 7. Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS)
  • 8. The Biomedical Research Network in Cancer (CIBERONC); Pancreatic and Biliopancreatic Surgery Unit, Hospital Universitario Ramón y Cajal
  • 9. Pancreatic and Biliopancreatic Surgery Unit, Hospital Universitario Ramón y Cajal
  • 10. Department of Pathology, Hospital Universitario Ramón y Cajal
  • 11. The Biomedical Research Network in Cancer (CIBERONC); Experimental Oncology, Molecular Oncology Program, Centro Nacional de Investigaciones Oncológicas (CNIO)
  • 12. Department of Radiation Oncology, Hospital Universitario Ramón y Cajal
  • 13. Molecular Epidemiology and Predictive Tumor Markers Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS); The Biomedical Research Network in Cancer (CIBERONC)
  • 14. Molecular Epidemiology and Predictive Tumor Markers Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS); The Biomedical Research Network in Cancer (CIBERONC); Faculty of Medicine, University of Alcalá de Henares
  • 15. Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS); Department of Cancer, Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBM); Cancer Stem Cell and Fibroinflammatory Group, Chronic Diseases and Cancer, Area 3, IRYCIS
  • 16. The Biomedical Research Network in Cancer (CIBERONC); Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS); Department of Cancer, Instituto de Investigaciones Biomédicas "Alberto Sols" (IIBM); Cancer Stem Cell and Fibroinflammatory Group, Chronic Diseases and Cancer, Area 3, IRYCIS
  • 17. Molecular Epidemiology and Predictive Tumor Markers Group, Area 3, Ramón y Cajal Health Research Institute (IRYCIS); The Biomedical Research Network in Cancer (CIBERONC); Biobank and Biomodels Platform (PT20/0045), ISCIII research and development platforms in biomedicine and health sciences, BioBank Hospital Ramón y Cajal-IRYCIS, Spanish National Biobanks Network (ISCIII Biobank Register No. B.0000678), Ramón y Cajal Health Research Institute (IRYCIS)

Description

Tumor organoids are three-dimensional (3D) ex vivo tumor models that recapitulate the biological key features of the original primary tumor tissues. Patient-derived tumor organoids have been used in translational cancer research and can be applied to assess treatment sensitivity and resistance, cell-cell interactions, and tumor cell interactions with the tumor microenvironment. Tumor organoids are complex culture systems that require advanced cell culture techniques and culture media with specific growth factor cocktails and a biological basement membrane that mimics the extracellular environment. The ability to establish primary tumor cultures highly depends on the tissue of origin, the cellularity, and the clinical features of the tumor, such as the tumor grade. Furthermore, tissue sample collection, material quality and quantity, as well as correct biobanking and storage are crucial elements of this procedure. The technical capabilities of the laboratory are also crucial factors to consider. Here, we report a validated SOP/protocol that is technically and economically feasible for the culture of ex vivo tumor organoids from fresh tissue samples of pancreatic adenocarcinoma origin, either from fresh primary resected patient donor tissue or patient-derived xenografts (PDX). The technique described herein can be performed in laboratories with basic tissue culture and mouse facilities and is tailored for wide application in the translational oncology field.

Notes

This study was supported by funding from the Plataforma biobancos y biomodelos - Unidades de las Plataformas ISCIII de apoyo ala I+D+i en Biomedicina y Ciencias de la Salud (PT20/00045), The European Union's Horizon 2020 Research and Innovation Programme under grant agreement No. 857381, project VISION (Strategies to strengthen scientific excellence and innovation capacity for early diagnosis of gastrointestinal cancers), Intramural call for new research projects for clinical researchers and emerging research groups IRYCIS (2021/0446) and the TRANSCAN II project JTC 2017 call "Establishing an algorithm for the early diagnosis and follow-up of patients with pancreatic neuroendocrine tumours (NExT)", grant number 1.1.1.5/ ERANET/20/03. The biological samples used in this protocol were provided by the BioBank Hospital Ramón y Cajal- IRYCIS (B.0000678) and integrated into the Biobanks and Biomodels Platform of the ISCIII (PT20/00045). We would also like to thank Yvonne Kohl, Agapi Kataki Vita Rovita, and Thorsten Knoll for their invaluable support to develop this protocol as part of the NExT and VISION projects.

Files

doi_org103791_65229.pdf

Files (936.3 kB)

Name Size Download all
md5:b4dc42e76b194892d7f80915108b81a3
936.3 kB Preview Download

Additional details

Funding

European Commission
VISION - Strategies to strengthen scientific excellence and innoVation capacIty for early diagnoSIs of gastrOintestinal caNcers 857381